MedTrace Logo

Vunakizumab Combined With Recaticimab in Subjects With Moderate to Severe Plaque Psoriasis and Dyslipidemia

NCT07373847 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-28

No results posted yet for this study

Summary

The aim is to evaluate the safety and efficacy of vunakizumab combined with recaticimab versus vunakizumab combined with placebo in the treatment of plaque psoriasis with dyslipidemia.

Conditions

Interventions

DRUG

vunakizumab and recaticimab.

Adult patients (\>18 years) with moderate-to-severe psoriasis who will start treatment with either vunakizumab and recaticimab.

DRUG

vunakizumab and placebo

Adult patients (\>18 years) with moderate-to-severe psoriasis who will start treatment with either vunakizumab and placebo.

Sponsors & Collaborators

  • Xiangya Hospital of Central South University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-20
Primary Completion
2027-06-30
Completion
2027-08-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07373847 on ClinicalTrials.gov